TBC Bristol-Myers Squibb Australia Pty Ltd
Product name
TBC
Accepted date
Mar-2024
Active ingredients
nivolumab
Proposed indication
Indicated for the neoadjuvant treatment of patients with resectable NSCLC.
Application type
C (new indication)
Publication date
Mar-2024